Apolipoprotein e and change in episodic memory in blacks and whites

Neuroepidemiology

Volumn 40, Issue 3, 2013, Pages 211-219

  Barnes, L L ^a,b   Arvanitakis, Z ^a,b   Yu, L ^a,b   Kelly, J ^c   De Jager, P L ^d,e,f   Bennett, D A ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Apolipoprotein E; Cognitive decline; Episodic memory

Indexed keywords

APOLIPOPROTEIN E;

AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; COGNITION; COHORT ANALYSIS; DEMENTIA; DEPTH PERCEPTION; EDUCATIONAL STATUS; EPISODIC MEMORY; EUROPEAN AMERICAN; FEMALE; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PERCEPTUAL SPEED; RACE DIFFERENCE; SEMANTIC MEMORY; SENSORY SYSTEM PARAMETERS; SEX DIFFERENCE; WORKING MEMORY;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ALLELES; APOLIPOPROTEIN E4; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY DISORDERS; MEMORY, EPISODIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84873054474     PISSN: 02515350     EISSN: 14230208     Source Type: Journal    
DOI: 10.1159/000342778     Document Type: Article

References (62)

1. Tzourio C, Arima H, Harrap S, Anderson C, Godin O, Woodward M, et al: APOE genotype, ethnicity, and the risk of cerebral hemorrhage. Neurology 2008; 70: 1322-1328.
2. Winkler K, Hoffmann MM, Krane V, Marz W, Drechsler C, Wanner C: Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. Atherosclerosis 2010; 208: 197-202.
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
4. Wisdom NM, Callahan JL, Hawkins KA: The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol Aging 2011; 32: 63-74.
5. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349-1356.
6. Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, et al: Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003; 60: 185-189.
7. Graff-Radford NR, Green RC, Go RC, Hutton ML, Edeki T, Bachman D, et al: Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002; 59: 594-600.
8. Hendrie HC, Hall KS, Hui S, Unverzagt FW, Yu CE, Lahiri DK, et al: Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol 1995; 37: 118-120.
9. Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RC, et al: A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol 2011; 68: 1569-1579.
10. Murrell JR, Price B, Lane KA, Baiyewu O, Gureje O, Ogunniyi A, et al: Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol 2006; 63: 431-434.
11. Perry RT, Collins JS, Harrell LE, Acton RT, Go RC: Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. Am J Med Genet 2001; 105: 332-342.
12. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, et al: Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65: 89-93.
13. Mount DL, Ashley AV, Lah JJ, Levey AI, Goldstein FC: Is ApoE epsilon4 associated with cognitive functioning in African Americans diagnosed with Alzheimer disease? An exploratory study. South Med J 2009; 102: 890-893.
14. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, et al: The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998; 279: 751-755.
15. Tycko B, Lee JH, Ciappa A, Saxena A, Li CM, Feng L, et al: APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals. Arch Neurol 2004; 61: 1434-1439.
16. Maestre G, Ottman R, Stern Y, Gurland B, Chun M, Tang MX, et al: Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995; 37: 254-259.
17. Sahota A, Yang M, Gao S, Hui SL, Baiyewu O, Gureje O, et al: Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. Ann Neurol 1997; 42: 659-661.
18. Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE: The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 2003; 60: 1077-1081.
19. Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ: The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. J Am Geriatr Soc 2001; 49: 1148-1155.
20. Sawyer K, Sachs-Ericsson N, Preacher KJ, Blazer DG: Racial differences in the influence of the APOE epsilon 4 allele on cognitive decline in a sample of communitydwelling older adults. Gerontology 2009; 55: 32-40.
21. Harwood DG, Barker WW, Ownby RL, Mullan M, Duara R: Apolipoprotein E polymorphism and cognitive impairment in a bi-ethnic community-dwelling elderly sample. Alzheimer Dis Assoc Disord 2002; 16: 8-14.
22. Blair CK, Folsom AR, Knopman DS, Bray MS, Mosley TH, Boerwinkle E: APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005; 64: 268-276.
23. Borenstein AR, Mortimer JA, Wu Y, Jureidini-Webb FM, Fallin MD, Small BJ, et al: Apolipoprotein E and cognition in communitybased samples of African Americans and Caucasians. Ethn Dis 2006; 16: 9-15.
24. Kuller LH, Shemanski L, Manolio T, Haan M, Fried L, Bryan N, et al: Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 1998; 29: 388-398.
25. Adamson MM, Landy KM, Duong S, Fox-Bosetti S, Ashford JW, Murphy GM, et al: Apolipoprotein E epsilon4 influences on episodic recall and brain structures in aging pilots. Neurobiol Aging 2010; 31: 1059-1063.
26. De BS, Montesanto A, Martino C, Dato S, De RF, Bruni AC, et al: APOE polymorphism affects episodic memory among non demented elderly subjects. Exp Gerontol 2009; 44: 224-227.
27. Mayeux R, Small SA, Tang M, Tycko B, Stern Y: Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging 2001; 22: 683-689.
28. Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, et al: Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001; 56: 49-56.
29. Barnes LL, Shah RC, Aggarwal NT, Bennett DA, Schneider JA: The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia. Curr Alzheimer Res 2012; 9: 736-747.
30. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS: Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res 2012; 9: 648-665.
31. Arvanitakis Z, Bennett DA, Wilson RS, Barnes LL: Diabetes and cognitive systems in older black and white persons. Alzheimer Dis Assoc Disord 2010; 24: 37-42.
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
33. Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, et al: Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002; 17: 179-193.
34. Wechsler D: Wechsler Memory Scale-Revised Manual. San Antonio, Psychological Corporation, 1987.
35. Albert M, Smith LA, Scherr PA, Taylor JO, Evans DA, Funkenstein HH: Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci 1991; 57: 167-178.
36. Wilson RS, Barnes LL, Krueger KR, Hoganson G, Bienias JL, Bennett DA: Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc 2005; 11: 400-407.
37. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 1. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39: 1159-1165.
38. Kaplan EF, Goodglass H, Weintraub S: The Boston Naming Test. Philadelphia, Lea & Febiger, 1983.
39. Cooper JA, Sagar HJ: Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources. J Clin Exp Neuropsychol 1993; 15: 713-731.
40. Smith A: Symbol Digit Modalities Test Manual -Revised. Los Angeles, Western Psychological Services, 1982.
41. Ekstrom RB, French JW, Harman HH, Kermen D: Manual for Kit of Factor-Referenced Cognitive Tests. Princeton, Educational Testing Service, 1976.
42. Trenerry MR, Crosson B, DeBoe J, Leber WR: Stroop Neuropsychological Screening Test Manual. Odessa, Psychological Assessment Resources, Inc, 1989.
43. Benton AL, Sivan AB, Hamsher KD, Varney NR, Spreen O: Contributions to neuropsychological assessment, ed 2. New York, Oxford University Press, 1994.
44. Raven JC, Court JH, Raven J: Manual for Raven's Progressive Matrices and Vocabulary. Oxford, Oxford Psychologists Press, 1992.
45. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, et al: Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 1993; 71: 160-165.
46. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-1671.
47. Boyle PA, Wilson RS, Aggarwal NT, Arvanitakis Z, Kelly J, Bienias JL, et al: Parkinsonian signs in subjects with mild cognitive impairment. Neurology 2005; 65: 1901-1906.
48. Buchman AS, Boyle PA, Wilson RS, Beck TL, Kelly JF, Bennett DA: Apolipoprotein E e4 allele is associated with more rapid motor decline in older persons. Alzheimer Dis Assoc Disord 2009; 23: 63-69.
49. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
50. SAS Institute Inc: SAS/STAT ®User's Guide, Version 9.1.3. (8). Cary, SAS Institute Inc, 2004.
51. O'Hara R, Yesavage JA, Kraemer HC, Mauricio M, Friedman LF, Murphy GM Jr: The APOE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J Am Geriatr Soc 1998; 46: 1493-1498.
52. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, et al: The apolipoprotein e4 allele and decline in different cognitive systems over a 6-year period. Arch Neurol 2002; 59: 1154-1160.
53. Boyle PA, Buchman AS, Wilson RS, Kelly JF, Bennett DA: The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 2010; 34: 43-49.
54. Rosen VM, Sunderland T, Levy J, Harwell A, McGee L, Hammond C, et al: Apolipoprotein E and category fluency: evidence for reduced semantic access in healthy normal controls at risk for developing Alzheimer's disease. Neuropsychologia 2005; 43: 647-658.
55. de Frias CM, Bunce D, Wahlin A, Adolfsson R, Sleegers K, Cruts M, et al: Cholesterol and triglycerides moderate the effect of apolipoprotein E on memory functioning in older adults. J Gerontol B Psychol Sci Soc Sci 2007; 62: 112-118.
56. Lee BK, Glass TA, Wand GS, McAtee MJ, Bandeen-Roche K, Bolla KI, et al: Apolipoprotein e genotype, cortisol, and cognitive function in community-dwelling older adults. Am J Psychiatry 2008; 165: 1456-1464.
57. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
58. Manly JJ: Deconstructing race and ethnicity: implications for measurement of health outcomes. Med Care 2006; 44: S10-S16.
59. Wilson RS, Scherr PA, Bienias JL, Mendes de Leon CF, Everson-Rose SA, Bennett DA, et al: Socioeconomic characteristics of the community in childhood and cognition in old age. Exp Aging Res 2005; 31: 393-407.
60. Boardman JD, Barnes LL, Wilson RS, Evans DA, Mendes de Leon CF: Social disorder, APOE-E4 genotype, and change in cognitive function among older adults living in Chicago. Soc Sci Med 2012; 74: 1584-1590.
61. Chakraborty R, Kamboh MI, Ferrell RE: 'Unique' alleles in admixed populations: a strategy for determining 'hereditary' population differences of disease frequencies. Ethn Dis 1991; 1: 245-256.
62. Teruel BM, Rodriguez JJ, McKeigue P, Mesa TT, Fuentes E, Cepero AA, et al: Interactions between genetic admixture, ethnic identity, APOE genotype and dementia prevalence in an admixed Cuban sample; a cross-sectional population survey and nested case-control study. BMC Med Genet 2011; 12: 43.